Lit­tle Ar­sa­nis steers its on­ly clin­i­cal-stage ther­a­py to the scrap heap af­ter a PhII im­plo­sion

One of the biotechs that bare­ly man­aged to com­plete its IPO late last year end­ed up of­fer­ing fresh proof about just how dan­ger­ous it can be to back a drug de­vel­op­er.

Ar­sa­nis $ASNS, a Vi­en­na-based com­pa­ny co-found­ed by an­ti­body ex­pert Till­man Gern­gross, re­port­ed to­day that it is scrap­ping its on­ly clin­i­cal de­vel­op­ment pro­gram af­ter the Phase II pro­gram for its S. au­reus pneu­mo­nia ther­a­py failed to sur­vive an in­ter­im analy­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER